Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial

Influence of anti-Spike protein antibody levels on tocilizumab efficacy in hospitalized patients with severe COVID-19 pneumonia: a post-hoc analysis of the COVACTA trial

Abstract Background Our aim in this work is to find biomarkers to optimize therapy with IL-6 inhibitors, as not all clinical trials have shown clear benefits on mortality or mechanical ventilation progression. Given the link between delayed seroconversion and higher complication risks, we aim to tes...

Full description

Saved in:
Bibliographic Details
Main Authors: José Aguareles, Carles Forné, Ana García-Casas, Guillermo Santamaría-Corral, Daniel Carnevali-Ruiz, Gabriel Sotres-Fernández, Javier T Solera, Pablo Guisado-Vasco
Format: Article
Language:English
Published: BMC 2025-05-01
Series:BMC Infectious Diseases
Subjects:
Tocilizumab
SARS-CoV-2
COVID-19
Antibodies
Serostatus
IL-6 inhibitors
Online Access:https://doi.org/10.1186/s12879-025-11001-6
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12879-025-11001-6

Similar Items